Kamel Abou Hussein, MD

Articles by Kamel Abou Hussein, MD

Unmet Needs and Future Outlook for HER2-Targeted Therapies

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

December 4th 2025

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.

Exciting New Data for TNBC Therapies

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

December 4th 2025

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Disease State Information on TNBC

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 25th 2025

Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.

Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 25th 2025

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 18th 2025

Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.

Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 18th 2025

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

Benjamin P. Levy, MD Kamel Abou Hussein, MD Victoria Rizk, MD

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

ByBenjamin P. Levy, MD,Victoria Rizk, MD,Kamel Abou Hussein, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 11th 2025

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

The Role of ADCs in Different Subgroups

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 11th 2025

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 3rd 2025

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Background Information on Targeted Therapies in Breast Cancer

ByNeil M. Iyengar, MD,Kelly E. McCann, MD, PhD,Kamel Abou Hussein, MD,William J. Gradishar, MD,Sara A. Hurvitz, MD, FACP

November 3rd 2025

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

Latest Updated Articles

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD
Published: November 17th 2025 | Updated:

Kamel Abou Hussein, MD

Articles by Kamel Abou Hussein, MD

Unmet Needs and Future Outlook for HER2-Targeted Therapies

Exciting New Data for TNBC Therapies

Disease State Information on TNBC

Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

The Role of ADCs in Different Subgroups

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

Background Information on Targeted Therapies in Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer